Trade this ETF at your broker
Fund size | EUR 7 m |
Total expense ratio | 0.35% p.a. |
Replication | Physical (Full replication) |
Legal structure | ETF |
Strategy risk | Long-only |
Fund currency | USD |
Currency risk | Currency unhedged |
Volatility 1 year (in EUR) | 18.18% |
Inception/ Listing Date | 2 September 2022 |
Distribution policy | Accumulating |
Distribution frequency | - |
Fund domicile | Ireland |
Fund Provider | VanEck |
Fund Structure | Open-ended Investment Company (OEIC) |
UCITS compliance | Yes |
Administrator | State Street Fund Services (Ireland) Limited |
Investment Advisor | VanEck Asset Management B.V. |
Custodian Bank | State Street Custodial Services (Ireland) Limited |
Revision Company | KPMG Ireland |
Fiscal Year End | 31 December |
Swiss representative | FIRST INDEPENDENT FUND SERVICES AG |
Swiss paying agent | Helvetische Bank AG |
Tax data | Bundesanzeiger | |
Germany | 30% tax rebate | |
Switzerland | ESTV Reporting | |
Austria | Non-Tax Reporting Fund | |
UK | No UK Reporting |
Indextype | Total return index |
Swap counterparty | - |
Collateral manager | |
Securities lending | No |
Securities lending counterparty |
Vertex Pharmaceuticals, Inc. | 9.06% |
Regeneron Pharmaceuticals | 8.34% |
Moderna, Inc. | 7.53% |
Veeva Systems | 7.10% |
DexCom | 6.65% |
Illumina | 6.38% |
Alnylam Pharmaceuticals | 4.15% |
BioNTech SE | 3.83% |
Sarepta Therapeutics | 3.82% |
EXACT Sciences | 3.60% |
Health Care | 91.27% |
Consumer Discretionary | 2.77% |
Consumer Staples | 0.76% |
Basic Materials | 0.41% |
Other | 4.79% |
Broker | Rating | Savings plan offer | Brokerage fee | More information |
---|---|---|---|---|
free of charge | free of charge | More info | ||
free of charge | free of charge | More info | ||
free of charge | free of charge | More info | ||
free of charge | free of charge | More info | ||
free of charge | free of charge | More info |
YTD | +2.05% |
1 month | +1.10% |
3 months | +1.65% |
6 months | +6.28% |
1 year | -3.86% |
3 years | - |
5 years | - |
Since inception (MAX) | -8.53% |
2023 | -8.09% |
2022 | - |
2021 | - |
2020 | - |
Volatility 1 year | 18.18% |
Volatility 3 years | - |
Volatility 5 years | - |
Return per risk 1 year | -0.21 |
Return per risk 3 years | - |
Return per risk 5 years | - |
Maximum drawdown 1 year | -23.16% |
Maximum drawdown 3 years | - |
Maximum drawdown 5 years | - |
Maximum drawdown since inception | -28.23% |
Listing | Trade Currency | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
---|---|---|---|---|---|
gettex | EUR | CURE | - - | - - | - |
Borsa Italiana | EUR | CURE | - - | - - | - |
Borsa Italiana | EUR | - | CURE IM CUREUSIV | CURE.MI CUREINAV=SOLA | |
London Stock Exchange | GBP | CURG | CURG LN CUREUSIV | CURG.L CUREUSDINAV=SOLA | |
London Stock Exchange | USD | CURE | CURE LN CUREUSIV | CURE.L CUREUSDINAV=SOLA | |
SIX Swiss Exchange | CHF | CURE | CURE SE CUREUSIV | CURE.S CUREUSDINAV=SOLA | |
XETRA | EUR | CURE | CURE GY CUREUSIV | CURE.DE CUREINAV=SOLA |
Fund name | Fund Size in m € (AuM) | TER in % p.a. | Distribution policy | Replication method |
---|---|---|---|---|
iShares Healthcare Innovation UCITS ETF | 1,056 | 0.40% p.a. | Accumulating | Sampling |
Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C | 3 | 0.30% p.a. | Accumulating | Full replication |